The Value of Troponin as a Biomarker of Chemotherapy-Induced Cardiotoxicity

• Published in: Life (Basel, Switzerland) Switzerland), 2022-08, Vol.12 (8), p.1183
• Main Authors: Sorodoc, Victorita, Sirbu, Oana, Lionte, Catalina, Haliga, Raluca Ecaterina, Stoica, Alexandra, Ceasovschih, Alexandr, Petris, Ovidiu Rusalim, Constantin, Mihai, Costache, Irina Iuliana, Petris, Antoniu Octavian, Morariu, Paula Cristina, Sorodoc, Laurentiu
• Format: Article
• Language: English
• Subjects: Anthracycline; Asymptomatic; Beta blockers; Biomarkers; Calcium-binding protein; Cancer; Cancer therapies; cardiac dysfunction; Cardiac function; Cardiomyopathy; Cardiotoxicity; Cardiovascular disease; Chemotherapy; Classification; Congestive heart failure; Coronary artery; Coronary artery disease; Diabetes mellitus; Diagnosis; Dyslipidemia; Ejection fraction; Epidermal growth factor; Fibrillation; Growth factors; Heart diseases; Heart failure; Immunotherapy; Ischemia; Medical prognosis; Mortality; Myocardial ischemia; Review; Risk analysis; Risk assessment; Risk factors; Toxicity; Troponin; Vascular endothelial growth factor
• ISSN: 2075-1729; 2075-1729
• DOI: 10.3390/life12081183

In cancer survivors, cardiac dysfunction is the main cause of mortality. Cardiotoxicity represents a decline in cardiac function associated with cancer therapy, and the risk factors include smoking, dyslipidemia, an age of over 60 years, obesity, and a history of coronary artery disease, diabetes, atrial fibrillation, or heart failure. Troponin is a biomarker that is widely used in the detection of acute coronary syndromes. It has a high specificity, although it is not exclusively associated with myocardial ischemia. The aim of this paper is to summarize published studies and to establish the role of troponin assays in the diagnosis of cardiotoxicity associated with various chemotherapeutic agents. Troponin has been shown to be a significant biomarker in the diagnosis of the cardiac dysfunction associated with several types of chemotherapeutic drugs: anthracyclines, anti-human epidermal growth factor receptor 2 treatment, and anti-vascular endothelial growth factor therapy. Based on the data available at this moment, troponin is useful for baseline risk assessment, the diagnosis of cardiotoxicity, and as a guide for the initiation of cardioprotective treatment. There are currently clear regulations regarding the timing of troponin surveillance depending on the patient’s risk of cardiotoxicity and the type of medication administered, but data on the cut-off values of this biomarker are still under investigation.